Gouras G K, Xu H, Jovanovic J N, Buxbaum J D, Wang R, Greengard P, Relkin N R, Gandy S
Memory Disorders Center, Department of Neurology and Neuroscience, Cornell University Medical College, New York, New York, USA.
J Neurochem. 1998 Nov;71(5):1920-5. doi: 10.1046/j.1471-4159.1998.71051920.x.
Studies of processing of the Alzheimer beta-amyloid precursor protein (betaAPP) have been performed to date mostly in continuous cell lines and indicate the existence of two principal metabolic pathways: the "beta-secretase" pathway, which generates beta-amyloid (A beta(1-40/42); approximately 4 kDa), and the "alpha-secretase" pathway, which generates a smaller fragment, the "p3" peptide (A beta(17-40/42); approximately 3 kDa). To determine whether similar processing events underlie betaAPP metabolism in neurons, media were examined following conditioning by primary neuronal cultures derived from embryonic day 17 rats. Immunoprecipitates of conditioned media derived from [35S]methionine pulse-labeled primary neuronal cultures contained 4- and 3-kDa A beta-related species. Radiosequencing analysis revealed that the 4-kDa band corresponded to conventional A beta beginning at position A beta(Asp1), whereas both radiosequencing and immunoprecipitation-mass spectrometry analyses indicated that the 3-kDa species in these conditioned media began with A beta(Glu11) at the N terminus, rather than A beta(Leu17) as does the conventional p3 peptide. Either activation of protein kinase C or inhibition of protein phosphatase 1/2A increased soluble betaAPP(alpha) release and decreased generation of both the 4-kDa A beta and the 3-kDa N-truncated A beta. Unlike results obtained with continuously cultured cells, protein phosphatase 1/2A inhibitors were more potent at reducing A beta secretion by neurons than were protein kinase C activators. These data indicate that rodent neurons generate abundant A beta variant peptides and emphasize the role of protein phosphatases in modulating neuronal A beta generation.
迄今为止,对阿尔茨海默病β-淀粉样前体蛋白(βAPP)加工过程的研究大多在连续细胞系中进行,结果表明存在两条主要的代谢途径:“β-分泌酶”途径,可生成β-淀粉样蛋白(Aβ(1-40/42);约4 kDa);以及“α-分泌酶”途径,可生成较小的片段“p3”肽(Aβ(17-40/42);约3 kDa)。为了确定类似的加工事件是否是神经元中βAPP代谢的基础,对来自胚胎第17天大鼠的原代神经元培养物处理后的培养基进行了检测。来自[35S]甲硫氨酸脉冲标记的原代神经元培养物的条件培养基免疫沉淀物中含有4 kDa和3 kDa的Aβ相关物种。放射性测序分析表明,4 kDa条带对应于从Aβ(Asp1)位置开始的传统Aβ,而放射性测序和免疫沉淀-质谱分析均表明,这些条件培养基中的3 kDa物种在N端以Aβ(Glu11)开始,而不是像传统p3肽那样以Aβ(Leu17)开始。蛋白激酶C的激活或蛋白磷酸酶1/2A的抑制均可增加可溶性βAPP(α)的释放,并减少4 kDa Aβ和3 kDa N端截短Aβ的生成。与在连续培养细胞中获得的结果不同,蛋白磷酸酶1/2A抑制剂在减少神经元Aβ分泌方面比蛋白激酶C激活剂更有效。这些数据表明啮齿动物神经元可产生大量Aβ变体肽,并强调了蛋白磷酸酶在调节神经元Aβ生成中的作用。